Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly is viewed positively because its incretin franchise is delivering exceptional commercial momentum, with 3Q26 Mounjaro sales up 65% to $10.72B and Zepbound up 49% to $5.35B, while the company raised guidance by $5bn, signaling demand that still appears early in penetration and volume terms. Its broadening pipeline adds further support, as Foundayo is gaining traction, retatrutide and EloraTZP show strong efficacy in obesity and diabetes, and oncology and immunology assets such as Verzenio, Jaypirca, and Inluriyo extend growth beyond cardiometabolic care. More broadly, the company’s structural advantages, including patent protection through 2035+, manufacturing scale, and expanding international reimbursement and Medicare Bridge access, support sustained revenue and EPS growth even as pricing pressures and mix effects persist.

Eli Lilly is facing a negative fundamental setup because its obesity franchise growth could deteriorate faster than expected as pricing pressure and competition weigh on Mounjaro and Zepbound, while broader product risks also extend to Foundayo and recent launches like Ebglyss. Operating margins are likely to remain pressured if these sales trends weaken, causing EPS growth to slow and leaving the stock vulnerable to multiple compression toward 21x, despite appearing inexpensive on an about 8x EV/EBITDA basis. Valuation support looks limited given a string of earnings disappointments, guidance reductions, and management turnover, and any unforeseen quality or manufacturing issues could further undermine earnings quality.